PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
4.19%
Net income growth under 50% of CRWD's 19.99%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
12.38%
D&A growth well above CRWD's 19.81%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-125.40%
Negative yoy deferred tax while CRWD stands at 450.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
0.82%
Less SBC growth vs. CRWD's 10.91%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
68.49%
Well above CRWD's 39.87% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
-1149.94%
AR is negative yoy while CRWD is 36.96%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
-238.67%
Negative yoy inventory while CRWD is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
454.21%
AP growth of 454.21% while CRWD is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
13958.21%
Growth well above CRWD's 4.96%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-251.92%
Negative yoy while CRWD is 20.37%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
6.68%
Operating cash flow growth below 50% of CRWD's 71.11%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-25.94%
Negative yoy CapEx while CRWD is 51.15%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-401.52%
Negative yoy acquisition while CRWD stands at 9.64%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-18.66%
Both yoy lines negative, with CRWD at -745.64%. Martin Whitman would suspect an environment with fewer attractive securities or a strategic pivot to internal growth.
9.95%
We have some liquidation growth while CRWD is negative at -51.22%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
-129.93%
Both yoy lines negative, with CRWD at -9.64%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-8849.02%
Both yoy lines negative, with CRWD at -1998.58%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
100.00%
Debt repayment growth of 100.00% while CRWD is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-0.58%
Negative yoy issuance while CRWD is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
17.96%
Buyback growth of 17.96% while CRWD is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.